David Arkowitz - 30 Jun 2025 Form 4 Insider Report for KINETA, INC./DE (KANT)

Reporting relationship: Director
Issuer ticker: KANT
Reported as of: 30 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2025, 16:21:50 UTC
Prior SEC filing: 25 Jun 2025
Next SEC filing: 24 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Albert W. Vanderlaan, as Attorney-in-Fact

Key filing fact

David Arkowitz filed Form 4 for KINETA, INC./DE (KANT) on 02 Jul 2025.

Key facts

This page summarizes David Arkowitz's Form 4 filing for KINETA, INC./DE (KANT).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jul 2025, 16:21.

Change

Previous filing in this sequence was filed on 25 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001296999 Primary reporting owner

Arkowitz David

Relationship: Director
Address: C/O TUHURA BIOSCIENCES, INC., 10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA
Signature: /s/ Albert W. Vanderlaan, as Attorney-in-Fact
Signature date: 02 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KANT transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -16,571
Change %: -100%
Price
Shares after: 0
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KANT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -12,500
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 30 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $3.28
Footnotes: F1, F2, F5

KANT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -20,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 30 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $3.28
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David Arkowitz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").

Footnote F2

This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.

Footnote F3

The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022.

Footnote F4

At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.

Footnote F5

At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.